This is the first study to assess the utility of RETeval device in children under 3 years of age undergoing vigabatrin treatment.

LKC’s RETeval™ demonstrated high intra-visit reliability with responses consistent with the standard Espion ERG and may be beneficial for assessment of retinal toxicity in young children treated with vigabatrin.